Welcome to our dedicated page for Eagle Pharmaceut news (Ticker: EGRX), a resource for investors and traders seeking the latest updates and insights on Eagle Pharmaceut stock.
Eagle Pharmaceuticals (EGRX) is a fully integrated specialty pharmaceutical company advancing therapies in oncology, central nervous system disorders, and pediatric critical care. This page serves as the definitive source for official company announcements, clinical trial updates, and regulatory developments.
Investors and healthcare professionals will find curated press releases detailing FDA submissions, partnership agreements, and research breakthroughs. Our repository includes updates on product approvals, manufacturing advancements, and strategic initiatives across EGRX's therapeutic portfolio.
Key content categories include quarterly financial results, clinical study outcomes, intellectual property milestones, and market expansion efforts. All materials are sourced directly from company filings and verified announcements to ensure reliability.
Bookmark this page for streamlined access to EGRX's latest developments. For comprehensive tracking of the company's progress in addressing complex medical needs through innovative pharmaceuticals, we recommend checking back regularly.
Eagle Pharmaceuticals (EGRX) has entered into a $69 million royalty purchase agreement with Blue Owl Capital to sell its royalty interest in BENDEKA® (bendamustine hydrochloride injection) U.S. sales. The transaction provides immediate, non-dilutive capital to Eagle.
Under the agreement, Eagle will receive the upfront payment in exchange for a prespecified royalty interest for Q4 2024 and 100% thereafter, up to 1.3x the purchase price. After reaching this cap, future royalty payments will revert to Eagle.
The company plans to use the proceeds to fully repay its Credit Agreement, including $27.5 million in term loan and $25 million in revolving credit facility. Remaining funds will support general corporate purposes, including ongoing R&D programs like CAL02 for severe community-acquired bacterial pneumonia and EA 114 for hormone-receptor-positive metastatic breast cancer.
Eagle Pharmaceuticals (EGRX) has announced an amendment to its duration stockholder rights plan, doubling the initial purchase price of preferred share purchase rights from $10.00 to $20.00. The Rights Plan targets any person or group that acquires 10% ownership (15% for passive institutional investors) of company stock without Board approval.
The amendment responds to significant stock price dislocation and aims to increase potential dilution for unauthorized acquirers. The plan's primary objectives are to protect long-term stockholder value and prevent control acquisition through open market accumulation without fair compensation. The Rights Plan will automatically expire on October 30, 2025, unless rights are redeemed or exchanged earlier.
Eagle Pharmaceuticals (EGRX) has announced its intention to file Form 25 with the SEC to complete its delisting from the Nasdaq Global Market. The company's common stock was suspended from Nasdaq trading on October 3, 2024, due to non-compliance with listing requirements, and has been trading on the OTC Expert Market since October 4, 2024. The Form 25 filing, expected on or after November 25, 2024, will finalize the delisting process and deregister the stock under Section 12(b) of the Securities Exchange Act, reducing SEC reporting obligations.
Eagle Pharmaceuticals (OTCMKTS: EGRX) has appointed Christopher Krawtschuk as Chief Financial Officer, effective November 11, 2024. Krawtschuk replaces Steven Ratoff, who steps down as interim CFO but remains on the company's board. Krawtschuk brings extensive pharmaceutical sector experience, having previously served as CFO at bluebird bio and Jubilant Pharma. His background includes roles at Morphosys, where he helped build U.S. commercial operations, and Pfizer, where he provided financial leadership. He began his career at PricewaterhouseCoopers, holds a B.S. in Accounting, and is a licensed CPA.
Eagle Pharmaceuticals has implemented a duration stockholder rights plan in response to significant stock price dislocation and unsolicited third-party accumulation attempts. The plan grants stockholders one preferred share purchase right for each common stock share as of November 11, 2024. These rights become exercisable if any entity acquires or attempts to acquire 10% or more of outstanding common stock (15% for passive institutional investors). When exercisable, each right allows holders to purchase additional shares at $10.00, with a market value of twice the exercise price. The plan expires on October 30, 2025, unless redeemed earlier.
Eagle Pharmaceuticals (Nasdaq: EGRX) received a delisting notification from Nasdaq on August 21, 2024, due to its failure to timely file the Q2 2024 Form 10-Q. This follows a previous notice on August 1, 2024, where Nasdaq granted the company continued listing subject to specific conditions. Eagle must file its 2023 Annual Report by September 30, 2024, and both Q1 and Q2 2024 Form 10-Qs by October 31, 2024. The company plans to file a comprehensive Form 10-K, including restated financial information, and separate Form 10-Q filings to meet these deadlines. However, there's no guarantee that Eagle will meet the compliance dates or maintain its Nasdaq listing.
Eagle Pharmaceuticals received a delisting notification from Nasdaq on May 20, 2024, due to its failure to file key financial forms, including the Q3 2023 Form 10-Q, the 2023 Form 10-K, and the Q1 2024 Form 10-Q. The delisting process will commence if Eagle does not request a hearing by May 28, 2024, which will result in the suspension of their stock trading on May 30, 2024. Eagle plans to request a hearing to potentially extend their compliance period. However, there is no guarantee that such an extension will be granted or that they will regain compliance.
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) announced a Trial in Progress presentation for their ongoing Phase 2/3 study of intravenous amisulpride as a prevention of postoperative nausea and vomiting in pediatric patients at the SAMBA 2024 Annual Meeting. Preliminary results are expected in the first half of 2025. The study aims to evaluate the potential benefits of amisulpride therapy in pediatric patients.
FAQ
What is the current stock price of Eagle Pharmaceut (EGRX)?
What is the market cap of Eagle Pharmaceut (EGRX)?
